Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Alcidion has extended its contract to 5-years with Western Sussex Hospitals for Patientrack software worth $970,000.
  • Patientrack is a software that can be used on tablets and smartphones, that helps hospitals improve patient safety, quality of care and clinical staff efficiency.
  • The 5 year deal will end in 2024

Alcidion has extended its contract to 5-years with Western Sussex Hospitals for Patientrack software worth $970,000.

Patientrack is a software which can be used on tablets and smartphones allowing hospitals to improve patient safety, quality of care and clinical staff efficiency.

The software has the capability to notices vital signs from a patients bedside to then alert hospital staff through a device.

Western Sussex Hospitals in the United Kingdom first used the technology in 2012, making it one of the longest serving users of Patientrack. The 5 year deal will end in 2024.

Alcidion purpose is to make healthcare better with smart solutions that meet the needs of hospital and healthcare worldwide.

Alcidion Managing Director, Kate Quirke is happy with the deal.

“We are delighted to continue our close partnership with Western Sussex Hospitals NHS Trust – one of our foundation customers in the UK – for the continued use of Patientrack for another five years,” she said.

ALC by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.